Curious to keep this conversation going as SOC was the very thing that the crew was talking about in terms of informing trial design for the adult sR-aGvHD.
One thing I took away from the conference call that Tanushree Jain (BP Analyst) asked was on precisely that - whether they would be opting for a superiority trial or a non-inferiority trial, where the SOC would be used as the comparator.
Some light weekend reading assigned by Mr James :Comparisons of Superiority, Non-inferiority, and Equivalence Trials
Comparisons of Superiority, Non-inferiority, and Equivalence Trials
In the literature-
"There is no accepted standard-of-care treatment for SR-aGVHD [11, 34]. This is due to most studies in SR-aGVHD being retrospective, single-arm, phase 2 studies [8, 11, 35], which cannot be easily compared with current patient populations due to significant changes in not only supportive care but also prophylaxis of GVHD. In addition, there are a lack of standardized endpoints, small numbers of enrolled patients, and decreased survival rates, making it difficult to compare data across studies [6, 8]." [source: here]
If you read between the lines, should the Prof and his crew pursue a superiority trial against the current SOC for adult sR-aGvHD (which they are already deep in planning with the top minds in oncology as mentioned both last night and this morning), one might end up in a situation where ruxo might be booted out as rem-L steps up to the plate out-performing on all fronts. If I was an INCY holder, I'd be quaking right about now if the company hasn't made any plans to refine the DP that's currently being used after the patients become steroid-refractory (the stats are that 35-50% of patients end up like that (source: here).
If there's a ruxo V2.0, I'd love to see it.
@nosluggos, you mentioned - "Whether the difference be significant enough to justify stopping the trial (ie and approving for use) on Covid ARDS patients at the 30% or 45% readouts?"
I wonder what the null hypothesis for the trial... that would be something that would point us to the primary endpoint no?
Thoughts anyone?
- Forums
- ASX - By Stock
- MSB
- MSB Trading 2020 - a new dawn
MSB Trading 2020 - a new dawn, page-540
-
-
- There are more pages in this discussion • 12,531 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.370B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.17 | $2.938M | 2.467M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 70737 | $1.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 28690 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 44471 | 1.165 |
16 | 125573 | 1.160 |
9 | 146106 | 1.155 |
13 | 440061 | 1.150 |
3 | 16785 | 1.145 |
Price($) | Vol. | No. |
---|---|---|
1.170 | 14865 | 6 |
1.175 | 27727 | 9 |
1.180 | 62713 | 10 |
1.185 | 58570 | 8 |
1.190 | 18205 | 5 |
Last trade - 12.16pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |